Comparative Effects of Intragastric and Intraduodenal Administration of Quinine on the Plasma Glucose Response to a Mixed-Nutrient Drink in Healthy Men: Relations with Glucoregulatory Hormones and Gastric Emptying.

Abstract

In preclinical studies, bitter compounds, including quinine, stimulate secretion of glucoregulatory hormones [e.g., glucagon-like peptide-1 (GLP-1)] and slow gastric emptying, both key determinants of postprandial glycemia. A greater density of bitter-taste receptors has been reported in the duodenum than the stomach. Thus, intraduodenal (ID) delivery may be more effective in stimulating GI functions to lower postprandial glucose. We compared effects of intragastric (IG) and ID quinine [as quinine hydrochloride (QHCl)] administration on the plasma glucose response to a mixed-nutrient drink and relations with gastric emptying, plasma C-peptide (reflecting insulin secretion), and GLP-1. Fourteen healthy men [mean±SD age: 25±3y; BMI (in kg/m2): 22.5±0.5]received, on 4 separate occasions, in double-blind, randomly assigned order, 600 mgQHCl or control, IG or ID, 60min (IG conditions) or 30min (IG conditions) before a mixed-nutrient drink. Plasma glucose (primary outcome) and hormones were measured before, and for 2 h following, the drink. Gastric emptying of the drink was measured using a 13C-acetate breath test. Data were analyzed using repeated-measures 2-way ANOVAs (factors: treatment and route of administration) to evaluate effects of QHCl alone and 3-way ANOVAs (factors: treatment, route-of-administration, and time) for responses to the drink. After QHCl alone, there were effects of treatment, but not route of administration, on C-peptide, GLP-1, and glucose (P<0.05); QHCl stimulated C-peptide and GLP-1 and lowered glucose concentrations (IG control: 4.5±0.1; IG-QHCl: 3.9±0.1; ID-control: 4.6±0.1; ID-QHCl: 4.2±0.1 mmol/L)compared with control. Postdrink, there were treatment×time interactions for glucose, C-peptide, and gastric emptying, and a treatment effect for GLP-1 (all P<0.05), but no route-of-administration effects. QHCl stimulated C-peptide and GLP-1, slowed gastric emptying, and reduced glucose (IG control: 7.2±0.3; IG-QHCl: 6.2±0.3; ID-control: 7.2±0.3; ID-QHCl: 6.4±0.4 mmol/L) compared with control. In healthy men, IG and ID quinine administration similarly lowered plasma glucose, increased plasma insulin and GLP-1, and slowed gastric emptying. These findings have potential implications for lowering blood glucose in type 2 diabetes. This study was registered as a clinical trial with the Australian New Zealand Clinical Trials at www.anzctr.org.au as ACTRN12619001269123.